The application was registered November 18. The drug is declared as an injectable suspension. Mosagrogen is listed as the developer, manufacturer and holder of the future registration certificate.
Work on Forcemag was already underway in 2025. In the report of the Timiryazev Academy, it is stated that the drug underwent a study of general toxicity on laboratory animals. The customer for the work was LLC NPK Askont+.
Earlier, "veterinary medicine and Life" reported that the company TsBO Microecology, operating under the Evolink brand, had filed an application to register a new vaccines against salmonellosis in poultry.



